Stopping low back pain: Researchers discover molecular mechanism responsible for vertebral column degeneration

Italian researchers at the Catholic University of Sacred Heart in Rome found an important molecular mechanism responsible for low back pain and other acute vertebral problems like cervical axial pain, all due to aging and degeneration of the vertebral column.

The team led by Dr. Luigi Aurelio Nasto and Enrico Pola also developed an to inhibit this degenerative mechanism, by blocking its principal culprit, the molecule, "NF-kB" and tested it successfully in mice. The study was carried out in collaboration with the University of Pittsburgh research team led by Paul Robbins, James Kang and Nam Vo.

Researchers reported their findings in the February 16 online edition of the journal Spine.

Nasto and Pola found that high concentration of NF-kB causes the degeneration of (the structures that separate and damp the vertebrae), a degenerative process that could affect also young adults (30 year old), especially if they adopt a sedentary lifestyle. In other words when NF-kB becomes overactive, it triggers a series of deleterious reactions that ultimately affect the physiological structure of the vertebral column.

Due to aging, obesity and , intervertebral discs degenerate, leading to the progressive stiffening of the column. The intervertebral disc degeneration is responsible for syndromes such as or neck that affects a large proportion of the .

Back pain and neck pain are ranked among the leading causes of lost working hours and disability in adults Italian scientists found the mechanism behind the degenerative processes of the column. They studied mice that are genetically programmed to age rapidly (progeroid mice). The of normal mice is 2 years. The progeroid mice age more quickly and have a lifespan of 8 months. The progeroid mice perfectly mimic the process of spine degeneration that occur in old people and young adults who suffer from low back pain.

The researchers found that NF-kB plays a role in the degeneration of the spine. NF-kB is a transcription factor, it modulates the activation of specific target genes. Researchers found that NF-kB activates many genes related to inflammation and turn off anti-inflammatory protective genes. Moreover in many studies NF-kB was found hyperactive in both the spines of old and old people.

The results of the Italian research suggest that NF-kB induces the onset of deleterious inflammatory processes and inhibit anti-inflammatory mechanisms. Moreover "our study shows that by inhibiting NF-kB, we can stop spine degeneration", Dr. Nasto says. "Drugs that turn off or even only partially inactivate NF-kB could be used to prevent the degeneration of intervertebral discs in patients."

"In our study, we developed a specific drug, called NBD peptide, able to specifically inhibit the deleterious action of NF-kB – dr Pola explains. NBD has been already successfully tested by a US team in Pittsburgh to slow the course of muscular dystrophy in an animal model (NF-kB is also involved in this disease). This peptide will be soon tested in a clinical trial (phase I) to study its therapeutic effects on Duchenne muscular dystrophy".

According to Nasto and Pola, NBD may also be used to counteract the aging of the . "We hope to develop other selective inhibitors of NF-kB to slow the degeneration of intervertebral discs" and cure , Pola concludes.

Provided by Catholic University of Rome

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Researchers find new drug target for lung cancer

Feb 16, 2012

Drugs targeting an enzyme involved in inflammation might offer a new avenue for treating certain lung cancers, according to a new study by scientists at the Salk Institute for Biological Studies.

Recommended for you

Growing a blood vessel in a week

Oct 24, 2014

The technology for creating new tissues from stem cells has taken a giant leap forward. Three tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown ...

Testing time for stem cells

Oct 24, 2014

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

Oct 23, 2014

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments